| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | EMMA | Common stock, $0.001 par value | Purchase | $710 | +500 | +0.2% | $1.42 | 257K | 22 Feb 2022 | Direct | |
| transaction | EMMA | Common stock, $0.001 par value | Purchase | $8.5K | +5.9K | +2.3% | $1.44 | 263K | 24 Feb 2022 | Direct | F1 |
| transaction | EMMA | Common stock, $0.001 par value | Purchase | $10.9K | +7.2K | +2.74% | $1.51 | 270K | 28 Feb 2022 | Direct | F2 |
| transaction | EMMA | Common stock, $0.001 par value | Purchase | $9.9K | +6.6K | +2.89% | $1.50 | 235K | 28 Feb 2022 | By Fidelity Traditional IRA FBO Willis C. Lee | F3 |
| transaction | EMMA | Common stock, $0.001 par value | Purchase | $1.49K | +900 | +90% | $1.65 | 1.9K | 28 Feb 2022 | By Fidelity Roth IRA FBO Willis C. Lee |
| Id | Content |
|---|---|
| F1 | The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.42 to $1.44, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnotes (2) and (3) to this Form 4. |
| F2 | The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.41 to $1.54, inclusive. |
| F3 | The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.42 to $1.60, inclusive. |